Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One jab for two bugs: pfizer tests combo COVID-Flu vaccine

NCT ID NCT06237049

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Pfizer trial tested whether a single injection combining an updated COVID-19 vaccine and a flu vaccine is safe and triggers a strong immune response. The study involved 644 healthy adults aged 50 and older. Researchers measured side effects and antibody levels to see if the combo shot works as well as getting the vaccines separately.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Combination of a modified RNA COVID-19 vaccine and a recombinant influenza vaccine
What this could lead to
If successful, this could lead to a single annual shot that protects against both COVID-19 and flu, simplifying vaccination for older adults.
What could go wrong
This is an early-phase trial focused on safety and immune response, not yet on preventing illness. The combination may not work as well as separate shots, and side effects could be more common.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

644 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 50 years or older at Visit 1 (Day 1). * Participants who are willing and able to comply with all scheduled visits, the investigational plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol. Exclusion Criteria: * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). * History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study interventions. * Participants with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, temporal arteritis, psoriasis, and/or insulin-dependent diabetes mellitus. * Immunocompromised individuals with known or suspected immunodeficiency, determined by history and/or laboratory/physical examination. * Current heart disease, uncontrolled hypertension, or a prior history of myocarditis or pericarditis. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant, plan to become pregnant during the study, or are breastfeeding. * Prior history of ischemic stroke or transient ischemic attack. * Prior history of Guillain-Barré syndrome (GBS). * Participants with a calculated BMI of ≥35. * Receipt of chronic medications with known systemic immunosuppressant effects (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for the treatment or prevention of COVID 19 or those that are considered immunosuppressive, from 90 days before study intervention administration, or planned receipt throughout the study. * Vaccination with any investigational or licensed influenza vaccine within 6 months (180 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza. * Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (180 days) before study intervention administration. * Participation in other studies involving administration of an investigational product within 28 days prior to, and/or during, participation in this study. * Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members. * Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. * Current alcohol abuse or drug addiction that in the opinion of the investigator might interfere with the study conduct or completion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Influenza, human SARS-CoV-2 infection

Contacts and locations

Locations

  • ActivMed Practices & Research, LLC.

    Portsmouth, New Hampshire, 03801, United States

  • Bio-Kinetic Clinical Applications LLC DBA QPS-MO(Patient Screening Center)

    Springfield, Missouri, 65807, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri, 65802, United States

  • Bio-Kinetic Clinical Applications, LLD dba QPS-MO

    Springfield, Missouri, 65802, United States

  • Centricity Research Columbus Ohio Multispecialty

    Columbus, Ohio, 43213, United States

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911, United States

  • Clinical Research Associates Inc

    Nashville, Tennessee, 37203, United States

  • Clinical Research Atlanta

    Stockbridge, Georgia, 30281, United States

  • Clinical Research Consulting

    Milford, Connecticut, 06460, United States

  • Clinical Site Partners, LLC dba Flourish Research

    Winter Park, Florida, 32789, United States

  • Clinical Trials of Texas, LLC

    San Antonio, Texas, 78229, United States

  • DM Clinical Research - Bellaire

    Houston, Texas, 77081, United States

  • DM Clinical Research - MDC

    Tomball, Texas, 77375, United States

  • DM Clinical Research- Cyfair

    Houston, Texas, 77065, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • GW Medical Faculty Associates

    Washington D.C., District of Columbia, 20037, United States

  • GW Vaccine Research Unit

    Washington D.C., District of Columbia, 20037, United States

  • Headlands Research Orlando

    Orlando, Florida, 32819, United States

  • IMA Clinical Research San Antonio

    San Antonio, Texas, 78229, United States

  • Indago Research & Health Center, Inc

    Hialeah, Florida, 33012, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • Las Vegas Clinical Trials

    Las Vegas, Nevada, 89030, United States

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada, 89030, United States

  • Optimal Research

    Melbourne, Florida, 32934, United States

  • Optimal Research

    Peoria, Illinois, 61614, United States

  • Orange County Research Center

    Lake Forest, California, 92630, United States

  • Orange County Research Center

    Tustin, California, 92780, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

  • SMS Clinical Research

    Mesquite, Texas, 75149, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.